bluestar
Forum Guru
Topics: 236
Posts: 724
|
since women who took tamoxifen had more than twice the chance of developing endometrial cancer, why don't they use progesterone to even out this effect ust like HRT?
___________________
I leave no trace of wings in the air, but I am glad I have had my flight
|
| SDK
Forum Fanatic
Topics: 537
Posts: 1,587
|
HRT is used in menopause women in which the postmenopausal symptoms are due to dec: level of estrogen......while Rx breast cancer again tumor is sensitive to estrogen not progesterone...
mean in either condition estrogen is necessary to use....
Now a days progesterone is added to estrgen preparations in OCP & HRT....to dec: the side effect of estrogen alone......
___________________
Love humans,save humans & live like humans.
|
| chemamr
Forum Hero
Topics: 703
Posts: 4,463
|
i agree with the concept of SDK.
___________________
Any time something is written against me, I not only share the sentiment but feel I could do the job far better myself.
|
| bluestar
Forum Guru
Topics: 236
Posts: 724
|
let me clarify what I really meant. I mean, why dont' we use progestorone AND tamoxifen in breast cancer patients? since unopposed estrogen (tamoxifen in this case) can increase endometrial hyperplasia and cancer, while using progestone after estrogen can decrease this effect.
Any thoughts about this?
___________________
I leave no trace of wings in the air, but I am glad I have had my flight
|
| p53
Forum Guru
Topics: 51
Posts: 804
|
Tamoxifen is a partial agonist at the estrogen receptors. Its activity may be agonistic in some organs and blocking in anothers. It behaves as agonist in endometrium (slightly increases risk of cancer), but as antagonist in breast - that's why we use it to treat breast cancer. So, in breast tissue there is no need to oppose its action by progestins. Last studies indicated that progestins (progesterone) also behaves totally differently in breast and endometrium - in endometrium it opposes action of estrogens and decreases risk of cancer. In breast it actually INCREASES risk of cancer, i.e. SYNERGISES action of estrogens. Furthermore, with estrogens plus progestins in hormone replacement therapy for postmenopausal women, breast proliferation was more marked and localized to the terminal duct-lobular unit, which is the main site of development of breast cancer, than in women taking estrogen alone or with no replacement therapy.
Edited by p53 on 08/13/05 - 11:03 PM
___________________
"Everything should be made as simple as possible, but not simpler." - Albert Einstein
|
|
| |
| | | | | |
